News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
AstraZeneca Moves Plavix Rival Into Final Tests
February 2, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Feb 2 (Reuters) - AstraZeneca Plc said on Thursday it had moved an experimental blood-thinner -- a rival to industry blockbuster Plavix -- into final Phase III tests.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
AstraZeneca Pharmaceuticals LP
MORE ON THIS TOPIC
IN PARTNERSHIP WITH EVOTEC
Strategic Drug Development in a Funding Crisis: Expert Insights on Risk Profiling, Efficiency, and Innovation
October 13, 2025
·
8 min read
·
BioSpace Insights
IN PARTNERSHIP WITH CHARLES RIVER LABORATORIES
AI in CAR T Development: Lessons From the Front Lines
October 13, 2025
·
5 min read
·
BioSpace Insights
Radiopharmaceuticals
Sanofi Comes for Novartis’ Radiopharma Crown With ‘Clinically Meaningful’ Pancreatic Tumor Data
October 8, 2025
·
2 min read
·
Annalee Armstrong
Podcast
Shutdown Pauses New Drug Reviews, CDC Issues New COVID Guidance, CGT Meets on Mesa
October 8, 2025
·
1 min read
·
Heather McKenzie
